Literature DB >> 26722411

Advanced glycation endproducts regulate smooth muscle cells calcification in cultured HSMCs.

Hu-Qiang He1, Yong Liu1, Hong Zeng1, Xiao-Lei Sun1, Lei Zhang1, Xue-Lin Zhang1, Wen-Jun Liao1, Xiang-Yu Zhou1, Yan-Zheng He1.   

Abstract

OBJECTIVE: To investigate the mechanism of Advanced glycation end products (AGEs) promoting the calcification of smooth muscle cells.
METHODS: The successfully cultured smooth muscle cells were divided into three groups: normal culture group (group A), calcified culture group (group B), calcification + AGEs group (group C); the concentration of intracellular calcium ion was detected in each group; the promotion of AGEs on the calcification of HSMCs was confirmed by VON KOSSA staining; and the expressions of β-catenin, RAGE, β-catenin, OPG and E-cadherin protein were detected by immunofluorescence and western blot.
RESULTS: The morphology of the cells in each group showed that the amount of calcified plaques in calcification + AGES group were significantly higher than the calcification group. VON KOSSA staining showed that with increasing concentrations of AGE-BSA, the amount of its calcification gradually increased. Calcium concentration in Calcification + 20 mg/L AGEs group was significantly higher, followed by 40 mg/L AGEs group. The expression of β-catenin increased with the increasing concentrations of AGEs.
CONCLUSION: AGEs can promote the calcification of human femoral artery smooth muscle cells, with a concentration gradient effect. With increasing concentrations of AGEs, the expression of RAGE increased, indicating that AGEs-induced HSMCs proliferation was correlated with RAGE expression.

Entities:  

Keywords:  AGEs; HSMCs; OPG; RAGE; calcification; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26722411      PMCID: PMC4680356     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  16 in total

1.  Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes.

Authors:  Theo P Hill; Daniela Später; Makoto M Taketo; Walter Birchmeier; Christine Hartmann
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 2.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

Review 3.  Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts.

Authors:  Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  Mol Nutr Food Res       Date:  2007-09       Impact factor: 5.914

4.  Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

Authors:  Susan J Zieman; Vojtech Melenovsky; Lia Clattenburg; Mary C Corretti; Anne Capriotti; Gary Gerstenblith; David A Kass
Journal:  J Hypertens       Date:  2007-03       Impact factor: 4.844

Review 5.  [The role of AGEs for the pathogenesis of osteopenia in diabetes mellitus].

Authors:  Takehisa Yamamoto
Journal:  Clin Calcium       Date:  2006-08

6.  Local application of advanced glycation end products and intimal hyperplasia in the rabbit collared carotid artery.

Authors:  H M Crauwels; A G Herman; H Bult
Journal:  Cardiovasc Res       Date:  2000-07       Impact factor: 10.787

Review 7.  Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications.

Authors:  Giuseppina Basta
Journal:  Atherosclerosis       Date:  2007-09-10       Impact factor: 5.162

8.  Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.

Authors:  Takahisa Tanikawa; Yosuke Okada; Rena Tanikawa; Yoshiya Tanaka
Journal:  J Vasc Res       Date:  2009-06-30       Impact factor: 1.934

9.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

Authors:  Josephine M Forbes; Louis Teo Loon Yee; Vicki Thallas; Markus Lassila; Riccardo Candido; Karin A Jandeleit-Dahm; Merlin C Thomas; Wendy C Burns; Elizabeth K Deemer; Susan R Thorpe; Susan M Thorpe; Mark E Cooper; Terri J Allen
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

Review 10.  RAGE signaling in inflammation and arterial aging.

Authors:  Li Lin; Sungha Park; Edward G Lakatta
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  5 in total

Review 1.  Histone Lysine Methylation Modification and Its Role in Vascular Calcification.

Authors:  Ye-Chi Cao; Su-Kang Shan; Bei Guo; Chang-Chun Li; Fu-Xing-Zi Li; Ming-Hui Zheng; Qiu-Shuang Xu; Yi Wang; Li-Min Lei; Ke-Xin Tang; Wen-Lu Ou-Yang; Jia-Yue Duan; Yun-Yun Wu; Muhammad Hasnain Ehsan Ullah; Zhi-Ang Zhou; Feng Xu; Xiao Lin; Feng Wu; Xiao-Bo Liao; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

Review 2.  A novel role of cellular interactions in vascular calcification.

Authors:  Adham Sameer A Bardeesi; Jingwei Gao; Kun Zhang; Suntian Yu; Mengchao Wei; Pinming Liu; Hui Huang
Journal:  J Transl Med       Date:  2017-05-03       Impact factor: 5.531

Review 3.  The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function.

Authors:  Lucie Hénaut; Aurélien Mary; Jean-Marc Chillon; Saïd Kamel; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2018-05-29       Impact factor: 4.546

4.  AGEs/RAGE Promote Osteogenic Differentiation in Rat Bone Marrow-Derived Endothelial Progenitor Cells via MAPK Signaling.

Authors:  Yuping Wang; Chunxia Jiang; Zhongming Shang; Guochun Qiu; Gang Yuan; Kaiqiang Xu; Qingchun Hou; Yanzheng He; Yong Liu
Journal:  J Diabetes Res       Date:  2022-02-01       Impact factor: 4.011

5.  Advanced Glycation End Products Induce Proliferation and Migration of Human Aortic Smooth Muscle Cells through PI3K/AKT Pathway.

Authors:  Gang Yuan; Guangyan Si; Qingchun Hou; Zhaonan Li; Kaiqiang Xu; Yuping Wang; Weiming Wang; Xiongfei Xu; Lei Zhang; Xiaolei Sun; Huqiang He; Hong Zeng; Yong Liu
Journal:  Biomed Res Int       Date:  2020-07-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.